ABVX vs. IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, and GPCR
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
ABIVAX Société Anonyme vs.
ABIVAX Société Anonyme (NASDAQ:ABVX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
In the previous week, ABIVAX Société Anonyme had 6 more articles in the media than Immunocore. MarketBeat recorded 14 mentions for ABIVAX Société Anonyme and 8 mentions for Immunocore. Immunocore's average media sentiment score of 1.08 beat ABIVAX Société Anonyme's score of 0.23 indicating that Immunocore is being referred to more favorably in the news media.
Immunocore received 61 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 75.00% of users gave ABIVAX Société Anonyme an outperform vote while only 73.68% of users gave Immunocore an outperform vote.
ABIVAX Société Anonyme presently has a consensus price target of $38.00, indicating a potential upside of 457.18%. Immunocore has a consensus price target of $65.64, indicating a potential upside of 117.84%. Given ABIVAX Société Anonyme's stronger consensus rating and higher probable upside, equities analysts clearly believe ABIVAX Société Anonyme is more favorable than Immunocore.
47.9% of ABIVAX Société Anonyme shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ABIVAX Société Anonyme has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
ABIVAX Société Anonyme has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. ABIVAX Société Anonyme's return on equity of 0.00% beat Immunocore's return on equity.
Immunocore has higher revenue and earnings than ABIVAX Société Anonyme.
Summary
ABIVAX Société Anonyme and Immunocore tied by winning 8 of the 16 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
This page (NASDAQ:ABVX) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy ABVX Stock Free ABVX Stock Alerts